Appointments

Inventiva announces two appointments to its management team ahead of future key development milestones

Inventiva announces two appointments to its management team ahead of future key development milestones

October 17, 2018

Marie-Paule Richard appointed as Chief Medical Officer and David Nikodem as Vice President of US Operations

Daix (France), October 17, 2018– Inventiva S.A. (“Inventiva” or the “Company”), a biopharmaceutical company developing innovative therapies in non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), announces today the appointment of Dr Marie-Paule Richard, M.D., as Chief Medical Officer (CMO) and Dr David Nikodem, Ph.D., as Vice President of US Operations in anticipation of the Company’s next development milestones.

Dr Jean-Louis Abitbol, M.D., who has been Inventiva’s CMO for the past three years and at the helm of the Company’s medical development team, will retire at the end of April 2019. The arrival of Marie-Paule Richard as CMO today will ensure a smooth transition ahead of the coming key developments that are expected over the course of 2019 such as the presentation of top-line results from the Company’s Phase IIb FASST (For A Systemic Sclerosis Treatment) trial in early 2019 and the results from the Phase IIa iMProveS (Improve MPS treatment) trial during the second-half of 2019. Dr Richard will bring to Inventiva her extensive experience in clinical development and regulatory strategy. Her successful experience in both filing and finalising approvals with the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will be a key asset for the Company given its anticipated interactions with these regulatory agencies.

Inventiva will also benefit from the appointment of David Nikodem who joined the Company as Vice President of US Operations in September. His deep industry knowledge and experience of the US markets from both a biopharmaceutical and financial perspective will be critical in reinforcing the Company’s increasingly active presence in the United States. Dr Nikodem’s international profile, experience and instrumental roles at Ally Bridge Group, Exane Asset Management and BNP Paribas amongst others will surely be valuable to the development of Inventiva.

To mark these movements, Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “We look forward to welcoming Marie-Paule and David to the Inventiva team. Their international profiles combined with their healthcare and financial expertise will be critical in the achievement of new milestones, starting with the presentation of top-line results from the SSc trial in early 2019. Marie-Paule and David will also serve a crucial role in helping to reinforce our expanding presence abroad. My team and I would like to thank Jean-Louis for his continued commitment and dedication to Inventiva over the past years. He has indeed been an important pillar in Inventiva’s development and we already wish him all the best for his retirement next year.”

I am very pleased to be joining Inventiva during this pivotal time,” added Marie-Paule Richard. “I believe that Inventiva’s differentiated programs have real potential to address unmet medical needs and I am excited to be a contributing factor to the many developments that lie ahead of us.”

David Nikodem commented: “This is an exciting time for Inventiva, particularly given the coming development milestones that are to take place both in France and abroad. I am honoured to be joining the team and look forward to help bring novel therapies to patients on a global scale.;”

Biographies

Dr Marie-Paule Richard, M.D.

Marie-Paule Richard is a seasoned medical leader who brings a long and diverse international experience acquired in senior executive positions for leading pharmaceutical and biotechnology companies. She is particularly accredited in the field of clinical development strategy and regulatory affairs, having driven several drug approvals and international license agreements in both Europe and the United States.

Prior to joining Inventiva, Marie-Paule Richard acted as CMO of the Belgian biotech firm Tigenix from 2014, which was recently acquired by Takeda. Before this, she was the CMO of AiCuris GmbH from 2010 to 2012 in Germany and held several international management positions at Bristol Myers Squibb, Aventis Pharma, GlaxoSmithKline and Sanofi Pasteur. Marie-Paule Richard holds a medical degree from the University of Nancy in France, and a certification in Clinical Immunology among other qualifications.

Dr David Nikodem, Ph.D.

David Nikodem has a wide experience of over 15 years across all healthcare subsectors, as a portfolio manager, analyst and risk manager in both public equities and public investments listed in the United States, France and Hong Kong. He is based in the United States, in Washington, D.C.

Prior to joining Inventiva, David Nikodem founded Sapidus Partners LLC in 2014, a US-based consulting group, where he has acted as a senior consultant for Ally Bridge Group for the past four years, with a focus on the biopharmaceutical sector, and at which he will continue his efforts in parallel with his new role at Inventiva. Previously, he worked as a Portfolio Manager for Exane Asset Management in Paris (2010-2013), as a Director and Portfolio Manager for BNP Paribas in New York (2005-2009), and as a Senior Healthcare Analyst for Blumberg Capital Management in New York (2002-2005). David Nikodem has also previous experience as a Patent Examiner at the USPTO and as a basic science researcher at the National Institutes of Health. Dr Nikodem holds a Ph.D. in Biochemistry and Molecular Biology from Georgetown University and a double B.A. in Chemistry and in English Language and Literature from the University of Virginia.

Contacts

Inventiva
Frédéric Cren

Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick
Julien Trosdorf / Yannick Tetzlaff

Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations
monique@lifesciadvisors.com

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Dr Lucy Lu is appointed to the Inventiva Board of Directors

Dr Lucy Lu is appointed to the Inventiva Board of Directors

May 28, 2018

Daix (France), May 28, 2018 – Inventiva S.A. (“Inventiva” or the “Company”), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), announces today the appointment of Dr Lucy Lu to its Board of Directors.

Dr Lu has a wide experience of over 15 years in the biotech and healthcare sector as an investment banker, sell- side analyst and CFO/CEO of biotech companies listed in the United States. As such, she will bring additional expertise in finance and clinical development to Inventiva. Drawing on her experience and knowledge of the American market, Dr Lu will also advise and help the Company in its development in the United States.

Lucy Lu joins Inventiva following the Company’s €35.5 million capital increase on April 13, 2018, in which Sofinnova Crossover I SLP fund (“Sofinnova”) has participated for an amount of 10 million euros. In this respect, Sofinnova proposed Dr Lu’s appointment to Inventiva’s Board of Directors.

Alongside her role at Inventiva, Lucy Lu has been the President and Chief Executive Officer of Avenue Therapeutics since its inception in 2015. Prior to this, she was Executive Vice President and Chief Financial Officer of Fortress Biotech from 2012 to 2017. Before working in the biotech industry, Lu gained 10 years of experience in healthcare-related equity research and investment banking working at Citigroup Investment Research (2007-2012) amongst others. Lucy Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. She also obtained a B.A. from the University of Tennessee’s College of Arts and Science.

To mark this appointment, Frédéric Cren, Chief Executive Officer and cofounder of Inventiva, said: “We are very happy to welcome Lucy to our team. Her industry knowledge and experience of the U.S. market from a scientific, financial and managerial perspective will help us accelerate our development and achieve new milestones together;.”

“I am pleased to be joining the Inventiva Board of Directors,” added Dr Lu. “I believe that Inventiva is at the leading edge of innovation, and it is an honour to work with this team to help advance its novel and differentiated programs for life-threatening conditions that are not addressed with current therapies.”

Jacques Teurillat, Partner for the Crossover Fund at Sofinnova Partners, commented: “Dr Lucy Lu has a strong track record in the biotech space and brings industry experience, passion and savviness. She will be a great addition to Inventiva’s Board of Directors.”;

Contacts

Inventiva
Frédéric Cren

Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick
Julien Trosdorf / Yannick Tetzlaff

Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations
monique@lifesciadvisors.com

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board

Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board

May 30, 2017

Daix (France), 30 May 2017 – 07:30pm CEST – Inventiva (Euronext Paris – FR0013233012 – IVA), a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, announced today the appointment Dr Nanna Lüneborg to the board of Inventiva, succeeding Mr Philippe Goupit. With this appointment, Inventiva’s Board of Directors comprises eight directors (three women and five men), including four independent directors.

Nanna Lüneborg is a Principal of Novo Ventures, a leading global life science investor, which participated in the IPO of Inventiva in February 2017. Novo Ventures is part of Novo A/S, the holding and investment company of the Novo Nordisk foundation.

Nanna Lüneborg has a background in medical research and life science venture capital. She completed her undergraduate studies at University of Oxford, PhD in Neuroscience from University College London, and MBA from the University of Cambridge. Prior to joining Novo A/S, she was part of the life science investment team at Apposite Capital, a London-based venture capital firm specialising in healthcare. In 2012, she joined Novo A/S, where she has been part of both the seed and venture investment teams. She has previous board experience from a range of biotech companies spanning start-up to late stage development, most recently from the board of ObsEva, which completed an IPO on NASDAQ earlier this year. She currently serves on the boards of Orphazyme and Epsilon-3 Bio, in addition to Inventiva.

On behalf of the Board of Directors and the Company as a whole, we warmly thank Philippe for his contribution to Inventiva’s development and wish him every success in his future projects;,” commented Frédéric Cren, Chairman and CEO of Inventiva. To succeed him, we are very pleased to welcome Nanna to our Board of Directors. Nanna’s experience will be valuable at this key stage in our development with the results of three clinical trials expected in 2018. We look forward to the advice and contribution she will bring.”;

“I am very pleased to be joining Inventiva’s Board of Directors. Inventiva has a promising portfolio of advanced products in fields that are stirring up significant interest in the pharmaceuticals industry. Being able to demonstrate positive results in NASH1, systemic sclerosis and MPS VI would constitute a major step forward for millions of patients who are still not receiving effective treatment,” added Dr Lüneborg. “This is an exciting time for the Company. Following the successful IPO, which gives it the financial means to realise its ambitions, I look forward to working in close collaboration with Inventiva’s Board of Directors and management team as the company moves ahead in the next key stages of its development.

About Novo Ventures:

Novo Ventures is part of Novo A/S, a private limited liability company, wholly owned by the Novo Nordisk Foundation. The company is the holding company in the Novo Group and is responsible for managing the assets of the Foundation. Besides being the major shareholder in the Novo Group companies, including Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. It has offices in Copenhagen, San Francisco, Boston and London with a team of scientific and commercial experts actively supporting a portfolio of projects and companies. For further information visit www.novo.dk.

1 Non-Alcoholic Steatotic Hepatitis

Contacts

Inventiva
Frédéric Cren

Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick
Julien Trosdorf / Yannick Tetzlaff

Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations
monique@lifesciadvisors.com

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.